Exocrine Pancreatic Insufficiency Therapeutics Market by Forecast to 2027 – TMR

TMR

4 years ago

According to Transparency Market Research’s latest report on the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market for the historical period 2017–2018 and forecast period 2019–2027, rise in prevalence of cystic fibrosis and chronic pancreatitis to escalate the growth of global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market. Moreover, rising cases of diabetes are expected to fuel growth of the exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market
According to the report, the global exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market was valued at US$ 3.9 Bn in 2018 and is anticipated to expand at a CAGR of 7.2% from 2019 to 2027

To know the scope of our report Get a Sample on Exocrine Pancreatic Insufficiency (EPI) Therapeutics and Diagnostics Market

Rise in Focus on Research & Development and Surge in Number of People with Diabetes Mellitus: Key Drivers of Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market

EPI is caused by insufficient secretion of pancreatic enzymes such as amylase, lipase, and protease and/ or sodium bicarbonate. Several disorders including different types of diabetes are associated with significantly increased risk for exocrine pancreatic insufficiency (EPI). For instance, according to an article published in Current Diabetes Reports, states that the prevalence of exocrine pancreatic insufficiency (EPI) is higher in type 1 diabetes than in type 2 diabetes. Thus, surge in number of people with diabetes is a key factor anticipated to drive the growth of exocrine pancreatic insufficiency (EPI) therapeutics & diagnostics market
Sedentary lifestyle and unhealthy diet are leading to surge in prevalence & incidence of diabetes. For instance, according to an article published in Diabetes Research and Clinical Practice, globally the prevalence of diabetes was 463 million in 2019 and is rising to 578 million by 2030
This is augmenting the demand for new treatment. To address these demands, the key players are investing in the research and development activities to develop and introduce new exocrine pancreatic insufficiency therapeutics thereby boosting the growth of market. For instance, AzurRx is developing a yeast-derived lipase, MS1819, which has been engineered to have superior enzymatic activity as compared to current treatments

Request the Coronavirus Impact Analysis on this Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=2748

Increase in Prevalence of Chronic Pancreatitis and Cystic Fibrosis Propel Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market Growth

Cystic fibrosis is the most common cause of exocrine pancreatic insufficiency. Around 50% of infants with cystic fibrosis have exocrine pancreatic insufficiency at birth, and another 25% develop it within six months. An additional 15% develop exocrine pancreatic insufficiency sometime in childhood or early adulthood.
Thus, rise in the global incidence of cystic fibrosis and chronic pancreatitis is one of the major factors driving the exocrine pancreatic insufficiency therapeutics & diagnostics market

Stringent FDA Regulations to Hamper Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market

Pancreatic enzyme replacement therapy (PERT) using pancrelipase products, which are mostly purified from the porcine pancreas, has been tested widely for exocrine pancreatic insufficiency associated with pancreatic diseases. Pancreatic enzyme products have been available as over-the-counter drugs in many regions for several years.
However, some drug regulatory agencies, including the U.S. Food and Drug Administration (FDA), have instructed that manufacturers obtain regulatory approvals before marketing their products because of possible adverse effects and inadequate effectiveness. These stringent FDA regulations have made approval of pancrelipase products difficult. This is leading to restrain the growth of market

Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market: Competitive Landscape

This report profiles major players in the global exocrine pancreatic insufficiency therapeutics & diagnostics market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
The global exocrine pancreatic insufficiency therapeutics & diagnostics market is highly fragmented, with the presence of a number of international as well as regional players
Leading players operating in the global exocrine pancreatic insufficiency therapeutics & diagnostics market
- AbbVie, Inc
- Allergan plc.
- Nordmark Arzneimittel GmbH & Co. KG
- Digestive Care, Inc.
- Janssen Pharmaceuticals, Inc.
- Cilian AG
- Anthera Pharmaceuticals, Inc
- AzurRx Biopharma, Inc.

Buy _ Research Report Now – https://www.transparencymarketresearch.com/checkout.php?rep_id=2748&ltype=S

Global Pancreatic Insufficiency (EPI) Therapeutics & Diagnostics Market: Key Developments

Key players in the global exocrine pancreatic insufficiency therapeutics & diagnostics market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global exocrine pancreatic insufficiency therapeutics & diagnostics market. A few expansion strategies adopted by players operating in the global exocrine pancreatic insufficiency therapeutics & diagnostics market are:

In April 2020, AzurRx Biopharma, Inc. has received Institutional Review Board (IRB) approval of its Phase 2 OPTION 2 clinical trial protocol to investigate MS1819 in cystic fibrosis (CF) patients with exocrine pancreatic insufficiency (EPI)
In April 2020, AzurRx Biopharma, Inc. has entered into a manufacturing agreement with Delpharm for the clinical drug product supply of its MS1819 therapy for exocrine pancreatic insufficiency (EPI)
In February 2020, Vivus Inc. announced that the U.S. Food and Drug Administration has approved the supplemental New Drug Application (sNDA) for PANCREAZE. PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions

The report on the global exocrine pancreatic insufficiency therapeutics & diagnostics market discussed individual strategies, followed by company profiles of manufacturers of exocrine pancreatic insufficiency therapeutics. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global exocrine pancreatic insufficiency therapeutics & diagnostics market.